Financial Contrast: Oncomed Pharmaceuticals (NASDAQ:OMED) vs. CytRx Corporation (CYTR)
CytRx Corporation (NASDAQ: CYTR) and Oncomed Pharmaceuticals (NASDAQ:OMED) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitabiliy and valuation.
Valuation & Earnings
This table compares CytRx Corporation and Oncomed Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|CytRx Corporation||$200,000.00||448.03||-$49.29 million||($0.56)||-1.05|
|Oncomed Pharmaceuticals||$25.02 million||5.46||-$97.14 million||($2.89)||-1.26|
CytRx Corporation has higher revenue, but lower earnings than Oncomed Pharmaceuticals. Oncomed Pharmaceuticals is trading at a lower price-to-earnings ratio than CytRx Corporation, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
CytRx Corporation has a beta of 2.33, indicating that its stock price is 133% more volatile than the S&P 500. Comparatively, Oncomed Pharmaceuticals has a beta of 2.9, indicating that its stock price is 190% more volatile than the S&P 500.
Insider & Institutional Ownership
11.4% of CytRx Corporation shares are held by institutional investors. Comparatively, 44.5% of Oncomed Pharmaceuticals shares are held by institutional investors. 7.5% of CytRx Corporation shares are held by company insiders. Comparatively, 32.8% of Oncomed Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
This is a summary of recent ratings and price targets for CytRx Corporation and Oncomed Pharmaceuticals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
CytRx Corporation currently has a consensus target price of $3.50, suggesting a potential upside of 493.92%. Oncomed Pharmaceuticals has a consensus target price of $7.71, suggesting a potential upside of 112.51%. Given CytRx Corporation’s stronger consensus rating and higher possible upside, research analysts clearly believe CytRx Corporation is more favorable than Oncomed Pharmaceuticals.
This table compares CytRx Corporation and Oncomed Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
CytRx Corporation beats Oncomed Pharmaceuticals on 7 of the 13 factors compared between the two stocks.
CytRx Corporation Company Profile
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy. It is also involved in evaluating aldoxorubicin in a Phase IIb clinical trial in small cell lung cancer; a Phase II clinical trial in human immunodeficiency virus-related Kaposi’s sarcoma; a Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); a Phase Ib trial in combination with ifosfamide in patients with STS, and a Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It is engaged in the pre-clinical development for DK049, an anti-cancer drug conjugate that utilizes its Linker Activated Drug Release (LADR) technology.
Oncomed Pharmaceuticals Company Profile
OncoMed Pharmaceuticals, Inc. (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer’s growth, resistance, recurrence and metastasis. The Company’s therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11). Demcizumab is a humanized monoclonal antibody that inhibits Delta-like Ligand 4 (DLL4) in the Notch signaling pathway. Tarextumab is a human monoclonal antibody that binds to both the Notch2 and Notch3 receptors.
Receive News & Ratings for CytRx Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytRx Corporation and related companies with MarketBeat.com's FREE daily email newsletter.